These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 2049506)
1. Predictive probability in clinical trials. Grieve AP Biometrics; 1991 Mar; 47(1):323-9; discussion 330. PubMed ID: 2049506 [TBL] [Abstract][Full Text] [Related]
2. Monitoring clinical trials based on predictive probability of significance. Choi SC; Pepple PA Biometrics; 1989 Mar; 45(1):317-23. PubMed ID: 2720057 [TBL] [Abstract][Full Text] [Related]
4. The performance of the O'Brien-Fleming multiple testing procedure in the presence of intraclass correlation. Lui KJ Biometrics; 1994 Mar; 50(1):232-6. PubMed ID: 8086606 [TBL] [Abstract][Full Text] [Related]
5. Group sequential designs for monitoring survival probabilities. Lin DY; Shen L; Ying Z; Breslow NE Biometrics; 1996 Sep; 52(3):1033-41. PubMed ID: 8805766 [TBL] [Abstract][Full Text] [Related]
6. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials. Brutti P; De Santis F; Gubbiotti S Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415 [TBL] [Abstract][Full Text] [Related]
7. Monitoring accumulating data in a clinical trial. Berry DA Biometrics; 1989 Dec; 45(4):1197-211. PubMed ID: 2611322 [TBL] [Abstract][Full Text] [Related]
8. The role of biometrics in clinical pharmacology. Rahlfs V Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):47-52. PubMed ID: 4924329 [No Abstract] [Full Text] [Related]
9. Confidence intervals for a normal mean following a group sequential test. Chang MN Biometrics; 1989 Mar; 45(1):247-54. PubMed ID: 2720054 [TBL] [Abstract][Full Text] [Related]
10. A stepdown procedure with feedback for identifying inferiority among three treatments. Lin CJ; Hayter AJ Biom J; 2008 Oct; 50(5):884-96. PubMed ID: 18932129 [TBL] [Abstract][Full Text] [Related]
11. Clinical trial designs based on sequential conditional probability ratio tests and reverse stochastic curtailing. Tan M; Xiong X; Kutner MH Biometrics; 1998 Jun; 54(2):682-95. PubMed ID: 9629648 [TBL] [Abstract][Full Text] [Related]
12. Detecting potential safety issues in clinical trials by Bayesian screening. Gould AL Biom J; 2008 Oct; 50(5):837-51. PubMed ID: 18932142 [TBL] [Abstract][Full Text] [Related]
13. Changing frequency of interim analysis in sequential monitoring. Lan KK; DeMets DL Biometrics; 1989 Sep; 45(3):1017-20. PubMed ID: 2790114 [TBL] [Abstract][Full Text] [Related]
14. A review of methods for futility stopping based on conditional power. Lachin JM Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130 [TBL] [Abstract][Full Text] [Related]
15. Calculation of sample size in survival trials: the impact of informative noncompliance. Jiang Q; Snapinn S; Iglewicz B Biometrics; 2004 Sep; 60(3):800-6. PubMed ID: 15339304 [TBL] [Abstract][Full Text] [Related]
16. A comment on interim analyses in crossover trials. Grieve AP; Senn S Biometrics; 1996 Dec; 52(4):1515-20. PubMed ID: 9019232 [TBL] [Abstract][Full Text] [Related]
17. Continuous toxicity monitoring in phase II trials in oncology. Ivanova A; Qaqish BF; Schell MJ Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702 [TBL] [Abstract][Full Text] [Related]
19. Analyzing time-to-event data in a clinical trial when an unknown proportion of subjects has experienced the event at entry. Balasubramanian R; Lagakos SW Biometrics; 2004 Jun; 60(2):335-43. PubMed ID: 15180658 [TBL] [Abstract][Full Text] [Related]
20. The Value of p-Value. Bahrami H Am J Gastroenterol; 2005 Jun; 100(6):1427-8. PubMed ID: 15929786 [No Abstract] [Full Text] [Related] [Next] [New Search]